Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) Stock Price & Analysis
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) — price $1.46 (0.00%), as of the Oct 2, 2026 trading session; market cap $8.46B. Expected results Oct 30, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Shanghai Pharmaceuticals Holding Co., Ltd · SHPMF · Healthcare · Medical - Distribution
Shanghai Pharmaceuticals Holding Co., Ltd. functions as an investment holding company deeply involved in various facets of China's pharmaceutical and healthcare sectors.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.46 | |
| Change on the day | 0.00% | |
| 52-week range | $1.46–$15.70 | |
| Market capitalisation | $8.46B | |
| Price / earnings (trailing) | 12.61 | |
| Beta (volatility vs the S&P 500) | 0.16 | |
| Dividends per share (last 12 months) | $0.08 | |
| Dividend yield (last 12 months) | 5.72% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Chronological order, not a duration scale. The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Shanghai Pharmaceuticals Holding Co. (SHPMF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
0 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read date unavailable · not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the SHPMF film — every key number, told as a short cinematic story
~2 min · open the film
What is Shanghai Pharmaceuticals Holding Co. (SHPMF), and what does it report?
Short answer · as of
Shanghai Pharmaceuticals Holding Co., Ltd. functions as an investment holding company deeply involved in various facets of China's pharmaceutical and healthcare sectors. Healthcare / Medical Distribution Headquarters: Shanghai Pharmaceutical Building, Shanghai, SHA, 200020, CN. It employs 49,608 people and is led by Qiuhua Yang. In Q2 FY2026 it reported revenue of $10.73B and net income of $310M. The market values it at $8.46B.
What do the latest results show for Shanghai Pharmaceuticals Holding Co. (SHPMF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $10.73B. Against analyst estimates the company has EPS beat 3 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $10.63B Aug 27, 2026
- Latest report · revenue estimate
- $11.17B Aug 27, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 27, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 27, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 27, 2026 | $10.63B | $11.17B | $0.0854 | $0.0971 |
| Apr 29, 2026 | $10.91B | $9.69B | $0.0551 | $0.0512 |
| Mar 31, 2026 | Provider row rejected | Provider row rejected | $0.1600 | $0.1950 |
| Oct 30, 2025 | $10.32B | $10.18B | $0.0267 | $0.0393 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $10.73B | $310M | $0.08 (diluted) |
| Q1 FY2026 | $11.12B | $209M | $0.06 (diluted) |
| Q4 FY2025 | $10.22B | $86M | $0.02 (diluted) |
| Q3 FY2025 | $10.95B | $103M | $0.03 (diluted) |
What are the financial strengths and risks for Shanghai Pharmaceuticals Holding Co. (SHPMF)?
Short answer
The distress and quality screens read Altman Z 2.03 · Piotroski F 6. Trailing ratios: ROE 6.2% · ROA 2.0% · current ratio 1.34 · earnings yield 7.9% · free-cash-flow yield 12.8%.
What should you watch next at Shanghai Pharmaceuticals Holding Co. (SHPMF)?
Short answer · as of
The next earnings report is expected on Oct 30, 2026.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
What has been published about Shanghai Pharmaceuticals Holding Co. (SHPMF)?
SHPMF Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Shanghai Pharmaceuticals sell beyond its own medicines?
The company distributes medicines and medical devices for manufacturers, supplies hospitals and pharmacies, operates chain and online pharmacies, and provides logistics, clinical support, prescription management and digital hospital services.
What is the SHPMF stock price today?
The last price recorded on this page for Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) is $1.46, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does SHPMF pay a dividend?
Yes. Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) shows a trailing 12-month dividend yield of 5.72%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (38 figures)
The 38 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 30 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.46 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T10:44:38.396Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $8.46B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-01. FMP quote timestamp: 2026-10-01T13:30:00.000Z. Captured from FMP at 2026-10-05T10:44:35.580Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Oct 30, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Shanghai Pharmaceuticals Holding Co., Ltd. functions as an investment holding company deeply involved in various facets of China's pharmaceutical and healthcare sectors. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $1.46–$15.70 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 12.61 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.16 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Distribution | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Shanghai Pharmaceutical Building, Shanghai, SHA, 200020, CN | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 49,608 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Qiuhua Yang | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $10.73B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $310M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-27.revenue_actual | Revenue · reported — report date 2026-08-27 | $10.63B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-27.revenue_estimated | Revenue · estimate — report date 2026-08-27 | $11.17B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-27.eps_actual | EPS · reported — report date 2026-08-27 | $0.0854 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-27.eps_estimated | EPS · estimate — report date 2026-08-27 | $0.0971 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-29.revenue_actual | Revenue · reported — report date 2026-04-29 | $10.91B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-29.revenue_estimated | Revenue · estimate — report date 2026-04-29 | $9.69B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-29.eps_actual | EPS · reported — report date 2026-04-29 | $0.0551 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-29.eps_estimated | EPS · estimate — report date 2026-04-29 | $0.0512 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-31.eps_actual | EPS · reported — report date 2026-03-31 | $0.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-31.eps_estimated | EPS · estimate — report date 2026-03-31 | $0.1950 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_actual | Revenue · reported — report date 2025-10-30 | $10.32B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_estimated | Revenue · estimate — report date 2025-10-30 | $10.18B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_actual | EPS · reported — report date 2025-10-30 | $0.0267 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_estimated | EPS · estimate — report date 2025-10-30 | $0.0393 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-30 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.03 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 6.2% · ROA 2.0% · current ratio 1.34 · earnings yield 7.9% · free-cash-flow yield 12.8% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.08 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 3 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 5.72% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-27.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($10.63B) with the recorded estimate ($11.17B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-27.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.0854) with the recorded estimate ($0.0971) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-27. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-27.revenue_actual,earn.history.depth.2026-08-27.revenue_estimated,earn.history.depth.2026-08-27.revenue_actual.comparison,earn.history.depth.2026-08-27.eps_actual.comparison,earn.history.depth.2026-08-27.eps_actual,earn.history.depth.2026-08-27.eps_estimated,earn.history.depth.2026-04-29.revenue_actual,earn.history.depth.2026-04-29.revenue_estimated,earn.history.depth.2026-04-29.eps_actual,earn.history.depth.2026-04-29.eps_estimated,earn.history.depth.2026-03-31.eps_actual,earn.history.depth.2026-03-31.eps_estimated,earn.history.depth.2025-10-30.revenue_actual,earn.history.depth.2025-10-30.revenue_estimated,earn.history.depth.2025-10-30.eps_actual,earn.history.depth.2025-10-30.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Shanghai Pharmaceuticals Holding Co., Ltd. functions as an investment holding company deeply involved in various facets of China's pharmaceutical and healthcare sectors. Its primary activities include the research, development, production, distribution, and retail of a diverse array of medical and health-related products. The company organizes its operations across four segments: Production, Distribution, Retail, and Others. Its extensive product portfolio encompasses chemical and biochemical medications, traditional Chinese medicines, health products, and medical devices. These target a broad spectrum of therapeutic areas, such as oncology, cerebrocardiovascular conditions, central nervous system disorders, general infections, immunology, digestive and metabolic diseases, and respiratory ailments, offering approximately 700 different drug formulations. Beyond manufacturing, Shanghai Pharmaceuticals provides comprehensive pharmaceutical supply chain solutions. This includes distribution, warehousing, logistics, and various value-added services catering to drug manufacturers and healthcare providers like hospitals, other distributors, and retail pharmacies. The company also manages a substantial retail footprint, operating around 2,000 chain pharmacies across 24 provinces, complemented by an online drug business. Furthermore, its service offerings extend to consulting, asset management, clinical trial support, medical aid programs, educational initiatives for patients and physicians, e-prescription management, and the development of remote and cloud hospital solutions. Established in Shanghai in 1994, where it maintains its headquarters, Shanghai Pharmaceuticals Holding Co., Ltd. operates as a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.